{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T16:37:48Z","timestamp":1793119068977,"version":"4.5.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100016838","name":"Berlin Mathematical School","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016838","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.hoc.2025.12.003","type":"journal-article","created":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T20:10:45Z","timestamp":1768680645000},"page":"289-301","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["The Role of Stem Cell Transplantation in Hodgkin Lymphoma"],"prefix":"10.1016","volume":"40","author":[{"given":"Hanan","family":"Alharthy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sairah","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hoc.2025.12.003_bib1","unstructured":"SEER\u2217Explorer: An interactive website for SEER cancer statistics (Internet) Surveillance Research Program, National Cancer Institute; 2025. (cited 2025 September 21). Available at: https:\/\/seer.cancer.gov\/statistics-network\/explorer\/.Datasource(s):SEERIncidenceData,November2024Submission(1975-2022), SEER 21 registries (excluding Illinois). Expected Survival Life Tables by Socio-Economic Standards."},{"issue":"9323","key":"10.1016\/j.hoc.2025.12.003_bib2","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","article-title":"Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin\u2019s disease: a randomised trial","volume":"359","author":"Schmitz","year":"2002","journal-title":"Lancet"},{"issue":"8852","key":"10.1016\/j.hoc.2025.12.003_bib3","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","article-title":"Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomised trial","volume":"341","author":"Linch","year":"1993","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.003_bib4","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1002\/ajh.26717","article-title":"Hodgkin lymphoma: 2023 update on diagnosis, risk-stratification, and management","volume":"97","author":"Ansell","year":"2022","journal-title":"Am J Hematol"},{"key":"10.1016\/j.hoc.2025.12.003_bib5","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1200\/JCO.22.02355","article-title":"Nivolumab and doxorubicin, vinblastine, and dacarbazine in early-stage unfavorable hodgkin lymphoma: final analysis of the randomized German hodgkin study group phase II NIVAHL trial","volume":"41","author":"Br\u00f6ckelmann","year":"2022","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.hoc.2025.12.003_bib6","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1056\/NEJMoa2405888","article-title":"Nivolumab+AVD in advanced-stage classic Hodgkin\u2019s lymphoma","volume":"391","author":"Herrera","year":"2024","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.003_bib7","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1056\/NEJMoa2206125","article-title":"Overall survival with brentuximab vedotin in stage III or IV Hodgkin\u2019s lymphoma","volume":"387","author":"Ansell","year":"2022","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.hoc.2025.12.003_bib8","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","article-title":"Brentuximab vedotin (SGN-35) for relapsed CD30-Positive lymphomas","volume":"363","author":"Younes","year":"2010","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.hoc.2025.12.003_bib9","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.hoc.2025.12.003_bib10","doi-asserted-by":"crossref","first-page":"2690","DOI":"10.1200\/JCO.2016.66.4482","article-title":"PD-L1 and PD-L2 genetic alterations define classical hodgkin lymphoma and predict outcome","volume":"34","author":"Roemer","year":"2016","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.003_bib11","article-title":"High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed\/refractory Hodgkin lymphoma","author":"Rancea","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"22","key":"10.1016\/j.hoc.2025.12.003_bib12","first-page":"2727","article-title":"Improved outcomes for relapsed\/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents","volume":"141","author":"Spinner","year":"2023","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.003_bib13","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/ajh.26827","article-title":"Checkpoint inhibitor-based salvage regimens prior to autologous stem cell transplant improve event-free survival in relapsed\/refractory classic Hodgkin lymphoma","volume":"98","author":"Desai","year":"2023","journal-title":"Am J Hematol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.003_bib14","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1182\/blood.V97.3.616","article-title":"A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model","volume":"97","author":"Moskowitz","year":"2001","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.003_bib15","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/j.bbmt.2013.09.018","article-title":"Simplified validated prognostic model for progression-free survival after autologous transplantation for Hodgkin lymphoma","volume":"19","author":"Hahn","year":"2013","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.003_bib16","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1093\/annonc\/mdx072","article-title":"Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma","volume":"28","author":"Br\u00f6ckelmann","year":"2017","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.003_bib17","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/bjh.12824","article-title":"F-18 FDG-PET predicts outcomes for patients receiving total lymphoid irradiation and autologous blood stem-cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"165","author":"Gentzler","year":"2014","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.003_bib18","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1038\/bmt.2013.88","article-title":"Pre-transplant FDG-PET-based survival model in relapsed and refractory Hodgkin\u2019s lymphoma: outcome after high-dose chemotherapy and auto-SCT","volume":"48","author":"Akhtar","year":"2013","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.003_bib19","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.3109\/10428194.2011.573889","article-title":"Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma","volume":"52","author":"Mocikova","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"23","key":"10.1016\/j.hoc.2025.12.003_bib20","doi-asserted-by":"crossref","first-page":"4934","DOI":"10.1182\/blood-2010-05-282756","article-title":"Pretransplantation functional imaging predicts outcome following autologous stem cell transplantation for relapsed and refractory Hodgkin lymphoma","volume":"116","author":"Moskowitz","year":"2010","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.003_bib21","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00277-016-2619-9","article-title":"Prognostic value of pretransplant FDG-PET in refractory\/relapsed Hodgkin lymphoma treated with autologous stem cell transplantation: systematic review and meta-analysis","volume":"95","author":"Adams","year":"2016","journal-title":"Ann Hematol"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.003_bib22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1053\/j.semnuclmed.2021.01.001","article-title":"FDG PET for assessment of autologous stem cell transplantation","volume":"51","author":"Jacene","year":"2021","journal-title":"Semin Nucl Med"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.003_bib23","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/annonc\/mdx791","article-title":"Autologous stem-cell transplantation after second-line brentuximab vedotin in relapsed or refractory Hodgkin lymphoma","volume":"29","author":"Herrera","year":"2018","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.003_bib24","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.bbmt.2015.07.018","article-title":"Results of a multicenter phase II trial of brentuximab vedotin as second-line therapy before autologous transplantation in relapsed\/refractory hodgkin lymphoma","volume":"21","author":"Chen","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.003_bib25","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1093\/annonc\/mdz009","article-title":"Brentuximab vedotin and ESHAP is highly effective as second-line therapy for Hodgkin lymphoma patients (long-term results of a trial by the Spanish GELTAMO group)","volume":"30","author":"Garcia-Sanz","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.003_bib26","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3324\/haematol.2019.243238","article-title":"Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON\/LLPC transplant BRaVE study","volume":"106","author":"Jos\u00e9 Kersten","year":"2021","journal-title":"Haematologica"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.003_bib27","doi-asserted-by":"crossref","first-page":"e562","DOI":"10.1016\/S2352-3026(21)00170-8","article-title":"Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1\/2 study","volume":"8","author":"Lynch","year":"2021","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.003_bib28","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1182\/blood.2022015423","article-title":"Response-adapted anti-PD-1\u2013based salvage therapy for Hodgkin lymphoma with nivolumab alone or in combination with ICE","volume":"139","author":"Mei","year":"2022","journal-title":"Blood"},{"issue":"28","key":"10.1016\/j.hoc.2025.12.003_bib29","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1200\/JCO.21.01056","article-title":"Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical hodgkin lymphoma","volume":"39","author":"Moskowitz","year":"2021","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.003_bib30","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1001\/jamaoncol.2022.7975","article-title":"Pembrolizumab added to ifosfamide, carboplatin, and etoposide chemotherapy for relapsed or refractory classic hodgkin lymphoma: a multi-institutional phase 2 investigator-initiated nonrandomized clinical trial","volume":"9","author":"Bryan","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.003_bib31","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1182\/blood.2020009178","article-title":"Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results","volume":"138","author":"Advani","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.003_bib32","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1182\/blood-2017-11-815183","article-title":"Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma","volume":"132","author":"LaCasce","year":"2018","journal-title":"Blood"},{"issue":"9980","key":"10.1016\/j.hoc.2025.12.003_bib33","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.003_bib34","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1182\/blood-2018-07-861641","article-title":"Five-year PFS from the AETHERA trial of brentuximab vedotin for Hodgkin lymphoma at high risk of progression or relapse","volume":"132","author":"Moskowitz","year":"2018","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.003_bib35","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.3324\/haematol.2023.282780","article-title":"Effect of cumulative dose of brentuximab vedotin maintenance in relapsed\/refractory classical Hodgkin lymphoma after autologous stem cell transplant: an analysis of real-world outcomes","volume":"108","author":"Wagner","year":"2023","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.hoc.2025.12.003_bib36","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1038\/s41409-025-02557-7","article-title":"Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: a systematic review and meta-analysis","volume":"60","author":"Sureda","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2025.12.003_bib37","doi-asserted-by":"crossref","first-page":"e19037","DOI":"10.1200\/JCO.2025.43.16_suppl.e19037","article-title":"Outcomes with nivolumab maintenance after autologous hematopoietic stem cell transplantation in relapsed\/refractory Hodgkin lymphoma: a systematic review and meta-analysis","volume":"43","author":"Aijaz","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2025.12.003_bib38","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1182\/blood-2021-148139","article-title":"A phase II single arm study of nivolumab as maintenance therapy after autologous stem cell transplantation in patients with hodgkin lymphoma at risk of relapse or progression","volume":"138","author":"Bachier","year":"2021","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.003_bib39","doi-asserted-by":"crossref","first-page":"32.e1","DOI":"10.1016\/j.jtct.2021.10.010","article-title":"Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with or without pembrolizumab maintenance therapy in patients with lymphoma","volume":"28","author":"Merryman","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.003_bib40","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1016\/S2352-3026(22)00318-0","article-title":"Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial","volume":"10","author":"Herrera","year":"2023","journal-title":"Lancet Haematol"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.003_bib41","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1093\/annonc\/mdn052","article-title":"Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin\u2019s lymphoma","volume":"19","author":"Sirohi","year":"2008","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.003_bib42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.hemonc.2017.05.009","article-title":"Long-term complications after hematopoietic cell transplantation","volume":"10","author":"Majhail","year":"2017","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.003_bib43","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.3324\/haematol.2021.280413","article-title":"Total late effect burden in long-term lymphoma survivors after high-dose therapy with autologous stem-cell transplant and its effect on health-related quality of life","volume":"107","author":"Smeland","year":"2022","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.003_bib44","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/dju207","article-title":"Risk of premature menopause after treatment for Hodgkin\u2019s lymphoma","volume":"106","author":"Swerdlow","year":"2014","journal-title":"J Natl Cancer Inst"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.003_bib45","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1093\/humupd\/dmad002","article-title":"Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review","volume":"29","author":"Drechsel","year":"2023","journal-title":"Hum Reprod Update"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.003_bib46","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1111\/ejh.12737","article-title":"Fertility in premenopausal women post autologous stem cell transplant with BEAM conditioning","volume":"97","author":"Lasica","year":"2016","journal-title":"Eur J Haematol"},{"issue":"12","key":"10.1016\/j.hoc.2025.12.003_bib47","doi-asserted-by":"crossref","first-page":"1488","DOI":"10.1200\/JCO-24-02782","article-title":"Fertility preservation in people with cancer: ASCO guideline update","volume":"43","author":"Su","year":"2025","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.003_bib48","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jamaoncol.2024.5627","article-title":"Transplant-free approach in relapsed hodgkin lymphoma in children, adolescents, and young adults: a nonrandomized clinical trial","volume":"11","author":"Daw","year":"2025","journal-title":"JAMA Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.hoc.2025.12.003_bib49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1182\/blood-2024-202537","article-title":"Pembrolizumab maintenance instead of autologous hematopoietic cell transplantation for patients with relapsed or refractory hodgkin lymphoma in complete response after pembrolizumab, gemcitabine, vinorelbine, and liposomal doxorubicin","volume":"144","author":"Moskowitz","year":"2024","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.003_bib50","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","article-title":"Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome","volume":"94","author":"Robinson","year":"2009","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.hoc.2025.12.003_bib51","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"Sureda","year":"2012","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.hoc.2025.12.003_bib52","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/hematology.2024000575","article-title":"When to use stem cell transplantation for classical Hodgkin lymphoma","volume":"2024","author":"Perales","year":"2024","journal-title":"Hematology"},{"issue":"7","key":"10.1016\/j.hoc.2025.12.003_bib53","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/bloodadvances.2017011122","article-title":"Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT?","volume":"2","author":"Peggs","year":"2018","journal-title":"Blood Adv"},{"issue":"9","key":"10.1016\/j.hoc.2025.12.003_bib54","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/j.bbmt.2019.05.025","article-title":"Lower graft-versus-host disease and relapse risk in post-transplant cyclophosphamide-based haploidentical versus matched sibling donor reduced-intensity conditioning transplant for Hodgkin lymphoma","volume":"25","author":"Ahmed","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.hoc.2025.12.003_bib55","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/s41409-019-0754-3","article-title":"Is this real life? Is this just fantasy? Decreased relapse following haploidentical transplant in Hodgkin\u2019s lymphoma with posttransplant cyclophosphamide","volume":"55","author":"Mussetti","year":"2020","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"10.1016\/j.hoc.2025.12.003_bib56","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Javier","year":"2023","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.hoc.2025.12.003_bib57","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1038\/s41409-020-0929-y","article-title":"Changes in patients population and characteristics of hematopoietic stem cell transplantation for relapsed\/refractory Hodgkin lymphoma: an analysis of the lymphoma working party of the EBMT","volume":"55","author":"Sureda","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.hoc.2025.12.003_bib58","first-page":"12","article-title":"The role of transplantation in Hodgkin lymphoma","author":"Maranzano","year":"2023","journal-title":"Front Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2025.12.003_bib59","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1111\/bjh.16664","article-title":"Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma","volume":"190","author":"Ahmed","year":"2020","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.hoc.2025.12.003_bib60","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1182\/blood.2024027197","article-title":"Outcomes of allogeneic HCT in Hodgkin lymphoma in the era of checkpoint inhibitors: a joint CIBMTR and EBMT analysis","volume":"146","author":"Perales","year":"2025","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.hoc.2025.12.003_bib61","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1182\/bloodadvances.2024015048","article-title":"Improved overall survival with checkpoint inhibition and allogeneic transplantation in relapsed Hodgkin lymphoma","volume":"9","author":"Tabbara","year":"2025","journal-title":"Blood Adv"}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001443?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858825001443?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:25:05Z","timestamp":1773955505000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858825001443"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":61,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S0889858825001443"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.003","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Role of Stem Cell Transplantation in Hodgkin Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}